Pulse Biosciences Inc. (PLSE)
Pulse Biosciences Inc. (PLSE) Stock Price, Analysis & Data
| Bid | 33.53 |
| Market Cap | 3.23B |
| Revenue (ttm) | 1.19M |
| Net Income (ttm) | -80.06M |
| Beta | 1.58 |
| EPS (ttm) | -1.17 |
| PE Ratio (ttm) | n/a |
| Forward PE | -39.16 |
| P/B (ttm) | 46.54 |
| P/S (ttm) | 2722.60 |
| Earnings Date | Nov 5, 2026 |
| Ask | 55.68 |
| Volume | 183,031 |
| Avg. Volume (20D) | 381,175 |
| Open | 43.43 |
| Previous Close | 43.32 |
| Day's Range | 43.38 - 46.91 |
| 52-Week Range | 12.56 - 46.91 |
| Analyst | Strong Buy |
| Price Target | 43 (-4.93%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferent...
Financial Performance
In 2025, Pulse Biosciences's revenue was 350K, an increase of undefined% compared to the previous year's 0. Earnings were -72.78M, an increase of 35.82%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for PLSE stock is "Strong Buy". The 12-month stock price forecast is 43, which is downside of 4.93% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
